Lonza breaks ground on second manufacturing facility in Singapore
Lonza Group and Bio*One Capital, a dedicated biomedical sciences investment management company in Asia, have broken ground on their large-scale commercial mammalian cell culture manufacturing facility at Tuas Biomedical Park in Singapore.
Lonza Group and Bio*One Capital, a dedicated biomedical sciences investment management company in Asia, have broken ground on their large-scale commercial mammalian cell culture manufacturing facility at Tuas Biomedical Park in Singapore.
This will be the second large-scale mammalian manufacturing plant in Singapore, and the third one globally that Lonza has built.
The construction of the Lonza Biologics Tuas shell, in the first phase, was initiated in February. The facility will be completed and become fully operational by 2011 at the latest, according to Lonza. The capital investment could amount to US$350m. Lonza Biologics Tuas will have up to four mammalian bioreactor trains, each with a flexible capacity of 1,000 up to 20,000 litres, inclusive of the respective purification units.
'In line with Lonza's strategy to develop its capabilities and expand the biopharmaceuticals business in the fast-growing Asian market, this facility marks an important milestone as Lonza reinforces its position as a global custom manufacturer of biopharmaceuticals, said Dr Stephan Kutzer, chairman of Lonza Biologics Tuas.
'The facility will be able to manufacture products with a wide array of processes, yields and technologies. This second Lonza facility in Singapore will meet the needs of a variety of customers and will address the growing global biologics demand.'
